Combination treatment of Src inhibitor Saracatinib with GMI, a Ganoderma microsporum immunomodulatory protein, induce synthetic lethality via autophagy and apoptosis in lung cancer cells

• Published in: Journal of cellular physiology Vol. 236; no. 2; pp. 1148 - 1157
• Main Authors: Chiu, Ling‐Yen, Hsin, I‐Lun, Tsai, Jen‐Ning, Chen, Chih‐Jung, Ou, Chu‐Chyn, Wu, Wen‐Jun, Sheu, Gwo‐Tarng, Ko, Jiunn‐Liang
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc 01.02.2021
• Subjects: Annexin V; Apoptosis; Autophagy; Caspase; Cell activation; Cell death; Clinical trials; Combined treatment; Cytotoxicity; Drug resistance; Enzyme inhibitors; Ganoderma; GMI; Immunomodulation; Immunomodulators; Iodides; Kinases; Lethality; Lung cancer; Phagocytosis; Propidium iodide; Proteins; saracatinib; Src; Src protein
• ISSN: 0021-9541; 1097-4652; 1097-4652
• DOI: 10.1002/jcp.29924

Saracatinib is an oral Src‐kinase inhibitor and has been studied in preclinical models and clinical trials of cancer therapy. GMI, a fungal immunomodulatory protein from Ganoderma microsporum, possesses antitumor capacity. The aim of this study is to evaluate the cytotoxic effect of combination trea...